ArticleJournal of Cancer2019
Lin28b is involved in curcumin-reversed paclitaxel chemoresistance and associated with poor prognosis in hepatocellular carcinoma.
Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Systematic Review and Meta-analysis Indicating Curcumin to Enhance the Synergistic Potential of Paclitaxel and Reduce Cell Viability, Tumor Volume, and Drug Resistance in Different Cancers.Current medicinal chemistry · 2025Pooled it
- Combination Chemotherapy with Selected Polyphenols in Preclinical and Clinical Studies-An Update Overview.Molecules (Basel, Switzerland) · 2023Pooled it
- Nanomaterials targeting cancer stem cells to overcome drug resistance and tumor recurrence.Frontiers in oncology · 2025Review
- The role of Lin28A and Lin28B in cancer beyond Let-7.FEBS letters · 2024Review
- Expression of Pluripotency Factors OCT4 and LIN28 Correlates with Survival Outcome in Lung Adenocarcinoma.Medicina (Kaunas, Lithuania) · 2024Article
- A Transcriptomic Biomarker for Predicting the Response to TACE Correlates with the Tumor Microenvironment and Radiomics Features in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Article
- Plant-derived natural products and combination therapy in liver cancer.Frontiers in oncology · 2023Review
- The role of LIN28B in tumor progression and metastasis in solid tumor entities.Oncology research · 2023Review
- Analysis on internal mechanism of zedoary turmeric in treatment of liver cancer based on pharmacodynamic substances and pharmacodynamic groups.Chinese herbal medicines · 2022Review
- Weighted gene co-expression network analysis reveals prognostic and diagnostic significance ofJournal of gastrointestinal oncology · 2022Article
- Article
- Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11.Neoplasia (New York, N.Y.) · 2021Article
- Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity.Pharmaceutics · 2020Review
- Integrated analysis of RNA-binding proteins in human colorectal cancer.World journal of surgical oncology · 2020Article
- Osthole resensitizes CD133Aging · 2020Article
- Association of LIN28B polymorphisms with chronic hepatitis B virus infection.Virology journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemoresistance remains a big challenge in hepatocellular carcinoma (HCC) treatment. Several studies indicated that RNA-binding protein Lin28B serves an oncogenic role in HCC, but its activity in HCC chemotherapy has never been assessed. In this study, we found that overexpression of Lin28B significantly increased the paclitaxel chemoresistance in two different HCC cells lines while silencing Lin28B reduced the chemoresistance in paclitaxel-resistance HCC cells. Curcumin, a natural anti-cancer agent, increased the sensitivity of HCC cells to paclitaxel through inhibiting NF-κB stimulated Lin28B expression both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.